Related Experiment Videos
[Bone turnover markers in tumor pathology with bone involvement]
J Napal Lecumberri1, J A Amado Señarís, C Pesquera
1Departamento de Medicina Interna, Hospital Nacional Marqués de Valdecilla, Facultad de Medicina, Santander.
Medicina Clinica
|April 7, 1990
Summary
Serum osteocalcin, alkaline phosphatase, and urinary hydroxyproline were evaluated in cancer patients. Osteocalcin showed limited usefulness in investigating neoplastic conditions, with other markers being more sensitive.
Area of Science:
- Oncology
- Biochemistry
- Medical Diagnostics
Background:
- Bone metastases and humoral malignant hypercalcemia (HMH) are serious complications of cancer.
- Biochemical markers are used to assess bone turnover and disease activity.
Purpose of the Study:
- To evaluate the utility of serum osteocalcin, alkaline phosphatase, and urinary hydroxyproline in patients with various bone metastases, HMH, and myeloma.
- To compare the sensitivity of these markers in different neoplastic conditions.
Main Methods:
- Measurement of serum osteocalcin and alkaline phosphatase levels.
- Quantification of urinary hydroxyproline excretion.
- Analysis of marker levels in patients with blastic, lithic, or mixed metastases, HMH, and myeloma.
Main Results:
- Osteocalcin showed limited significant increase in metastases, with alkaline phosphatase and hydroxyproline being more sensitive.
- In HMH, hydroxyproline levels were comparable to primary hyperparathyroidism, while osteocalcin was significantly increased but lower than in parathyroid disease.
- No significant changes in the evaluated markers were observed in myeloma patients.
Conclusions:
- Serum osteocalcin has minimal practical value for investigating neoplastic patients with bone involvement or HMH.
- Alkaline phosphatase and urinary hydroxyproline are more sensitive markers for detecting bone turnover abnormalities in these conditions.